Bioavailability, biodistribution, and toxicity of biozn-aas: a new zinc source. comparative studies in rats

Food fortification with a proper zinc compound is an economic and effective strategy to prevent zinc deficiency. BioZn-AAS, a zinc gluconate stabilized with glycine, was compared with zinc sulfate (reference standard), zinc hydroxide, and zinc gluconate, all of them labeled with 65Zn. This preclinical study was performed on Sprague-Dawley rats of both sexes, and the administered dose was 85 μg/kg of zinc. Bioavailability studies showed that absorption of BioZn-AAS was not statistically different than absorption from other sources in female rats (25.65% ± 2.20% for BioZn-AAS, 28.24% ± 4.60% for ZnSO4, 24.91% ± 4.02% for Zn[OH]2, and 25.51% ± 2.70% for Zn-gluconate). In the case of the male rats, absorption of BioZn-AAS (27.97% ± 4.20%) was higher (P<0.05) than that from the other compounds (23.15% ± 2.90% for ZnSO4, 22.62% ± 3.90% for Zn[OH]2, and 22.30% ± 3.90% for Zn-gluconate). Biodistribution studies demonstrated that the zinc from BioZn-AAS followed the same metabolic pathway as zinc from the other sources. Toxicity studies were performed with 50 female and 50 male rats. The value of oral lethal dose 50 (LD50) was 2000 mg/kg for female rats and 1900 mg/kg for male rats. Therefore, we conclude that BioZn-AAS has adequate properties to be considered a proper zinc compound for food fortification or dietary supplementation.